Ascend Advanced Therapies
Contract development and manufacturing organization (CDMO) specializing in cell and gene therapy manufacturing, including viral vector production for advanced therapies.
Notes
Ascend Advanced Therapies is a contract development and manufacturing organization (CDMO) focused on supporting the development and manufacturing of cell and gene therapies. The company provides end-to-end services for viral vector production, cell therapy manufacturing, and related process development.
Ascend offers manufacturing services for adeno-associated virus (AAV) vectors, lentiviral vectors, and other gene delivery systems used in gene therapy applications. The company serves pharmaceutical and biotechnology clients developing advanced therapies for genetic diseases, cancer, and other conditions.
In 2024, Ascend merged with ABL (formerly Advanced Bioscience Laboratories) to create an integrated U.S. hub for viral vector manufacturing, combining Ascend's cell and gene therapy expertise with ABL's extensive viral vector experience.
Ascend is a portfolio company of Abingworth, a leading life sciences investment firm.
Team
- Marc Perlmutter - Chief Executive Officer
- LinkedIn: linkedin.com/in/marc-perlmutter
Additional Research Findings
- Portfolio company of Abingworth
- CDMO for cell and gene therapy
- Merged with ABL in 2024
- Viral vector manufacturing (AAV, lentiviral)
- Rockville, Maryland headquarters
- End-to-end manufacturing services
- Focus on advanced therapies manufacturing
Sources
Investors
| Name | Location | Type | Stages | Portfolio |
|---|---|---|---|---|
| Abingworth | London, UK / Boston, USA | biotech-focused | seedseries-a+3 | 34 |